Back to top

Analyst Blog

Synergy Pharmaceuticals Inc. (SGYP - Snapshot Report) currently has no approved products. The company has progressed well with its pipeline in the last few quarters. SP-333 is one of the important candidates in Synergy Pharma’s pipeline, being developed for the treatment of inflammatory bowel diseases (IBD).

Synergy Pharma intends to move forward its proprietary next-generation guanylate cyclase-C (GC-C) agonist, SP-333, into a phase II study for the treatment of opioid-induced constipation (OIC) by year end. The phase II study (dose-ranging study) will be evaluating a 4-week regimen of the candidate in adults. The adults in the study have been taking opioid analgesics for chronic, non-cancer pain for a minimum of three months.

In the second quarter of 2013, Synergy Pharma successfully completed a phase I placebo-controlled, dose-escalating, multiple-dose study on SP-333 in patients with IBD.

Another interesting candidate at Synergy Pharma is plecanatide. Plecanatide is currently in a phase IIb study for the treatment of patients suffering from irritable bowel syndrome with constipation (IBS-C). Synergy Pharma expects to enroll the last patient for the study by year end and release top-line data from this study in the first quarter of 2014.

We expect investor focus to remain on updates regarding the development of the company’s pipeline. The successful development and commercialization of the candidates would be a major positive for Synergy Pharma.

However, the constipation market already includes Ironwood Pharmaceuticals/Forest Laboratories’ (IRWD - Analyst Report)/ Linzess.

Synergy Pharma currently carries a Zacks Rank #3 (Hold). Right now, Actelion Ltd. (ALIOF) looks attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.70 +4.23%
BANCO DO BR… BDORY 14.49 +3.87%
WEATHERFORD… WFT 23.71 +3.40%
MALLINCKROD… MNK 78.37 +3.19%
AIR INDUSTR… AIRI 9.89 +3.13%